Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2014

The Cytotoxic Effect of the BCL-2 Family of Proteins in Breast
Cancer Cells
Yamileth Chin
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biochemistry Commons, and the Medicine and Health Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3490

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

©Yamileth Chin
All Rights Reserved

2014

THE CYTOTOXIC EFFECT OF THE BCL-2 FAMILY OF PROTEINS IN
BREAST CANCER CELLS

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at
Virginia Commonwealth University

By

Yamileth Chin

Bachelor of Science, George Mason University, Fairfax, VA
Director: Hisashi Harada, Ph.D.
Professor, Department of Molecular Biology and Genetics

Virginia Commonwealth University
Richmond VA
August 2014

Acknowledgements
First and foremost, I want to thank my mentor and advisor, Dr. Hisashi Harada, for all his wisdom
and encouragement throughout the duration of the program. With a great scientific mind and
ideas, I learned to appreciate science at a different level and depth which has brought me to
writing this thesis.

I would like to extend my sincere gratitude to my laboratory members and friends Mark Hicks
and Dr. Wataru Nakajima for teaching me the necessary techniques to advance my research. I
have really enjoyed doing my research with such a great team. I also want to express my greatest
appreciation to Dr. Zendra Zehner and Dr. Andrew Yeudall for all of their support and advice. I
would like to give special thanks to Dr. Gail Christie for all of her guidance during my graduate
studies.

Lastly, I want to thank my friends, colleagues and professors who have supported me and served
as guidance to my future goals. Without their advice and support, I couldn’t have made it this far.

And as always, my love and deep appreciation goes to my beloved ones.

ii

TABLE OF CONTENTS
Acknowledgement

ii

List of Figures

v

List of Tables

vi

List of Abbreviations

vii

Abstract

viii

CHAPTER 1: INTRODUCTION
1.1 Cancer

1

1.2 Breast Cancer

2

1.3 Paclitaxel Treatment

5

1.4 Apoptosis

7

1.5 BCL-2 Family Proteins

10

1.6 MCL-1 and NOXA interaction

13

1.7 Previous studies

16

1.8 Hypothesis

18

CHAPTER 2: MATERIALS AND METHODS
2.1 Cell lines and cell culture

19

2.2 Chemicals and antibodies

20
iii

2.3 Plasmid transfection and lentivirus infection

20

2.4 Cell toxicity assay

21

2.5 Western blot analysis and Immunoprecipitation

21

2.6 IC50 Calculations

23

CHAPTER 3: RESULTS
Section 3.1: Breast cancer cell lines and their molecular characteristics

24

Section 3.2: Knock-down of MCL-1 induces cell death in breast cancer cells

25

Section 3.3: Overexpression of Noxa in breast cancer cells induces survival or cell death 26
Section 3.4: The expression of the BCL-2 family proteins in TN breast cancer cells

28

Section 3.5: The interaction of MCL-1 and Noxa is weak in Hs578 and strong in BT-20 30
Section 3.6: Paclitaxel sensitivity results of various breast cancer cell lines

34

CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS

36

References

39

VITA

44

iv

LIST OF FIGURES
Figure 1: Structural formula of Paclitaxel

6

Figure2: Paclitaxel as a mitotic stabilizer

7

Figure 3: Schematic of the extrinsic and intrinsic pathways of apoptosis

9

Figure 4: Sequence homology of the BCL-2 family of proteins

11

Figure 5: The BCL-2 family proteins as the main players of the intrinsic pathway

13

Figure 6: Noxa-induced MCL-1 degradation and BAK activation

15

Figure 7: Schematic of Paclitaxel-dependent MCL-1 degradation

17

Figure 8: MCL-1 knock-down in cell lines Hs578t and SKBR3

25

Figure 9: Expression levels of the BCL-2 family proteins in TN breast cancer cells

29

Figure 10: Noxa overexpression and its effect on MCL-1 protein levels in Hs578t and
BT-20

31

Figure 11: IP results of Noxa overexpression and MCL-1 in TN cells

32

Figure 12: Schematic representation of Noxa and MCL-1 interaction in TN cells

33

v

LIST OF TABLES
Table 1: Molecular classification of breast carcinoma

24

Table 2: Results of MCL-1 knock-down and Noxa overexpression in breast cancer cells
and MCF-10A

27

Table 3: IC50 values to Paclitaxel in breast cancer cells and MCF-10A

35

vi

LIST OF ABBREVIATIONS

ER: Estrogen receptor
PR: Progesterone receptor
HER2: Human epidermal growth factor receptor 2
TN: Triple negative
MCL-1: Myeloid cell leukemia-1
BCL-2: B-cell lymphoma-2
MOMP: Mitochondrial outer membrane permeabilization
PARP-1: Poly (ADP-ribose) polymerase-1

vii

The Cytotoxic Effect of the BCL-2 family of proteins in Breast
Cancer Cells
By Yamileth Chin, M.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Director: Hisashi Harada, Ph.D.

Abstract
Breast cancer is the second leading cause of death amongst women ages 20 to 59. Despite
advancements in cancer therapies, more research is necessary to improve the diagnoses and
treatment of several types of breast cancer. Paclitaxel (Taxol) is a commonly utilized anti-cancer
drug for various types of solid tumors. However, the molecular mechanism utilized by paclitaxel
to induce cell death is still elusive. Previous studies in our laboratory have shown that the proapoptotic BCL-2 family protein, BAK (BCL-2 homologous antagonist/killer) plays an important
role in paclitaxel-induced cell death. In untreated breast cancer cells, BAK is associated with the
anti-apoptotic BCL-2 family protein MCL-1 (myeloid leukemia cell differentiation protein). BAK
is activated with paclitaxel treatment in concert with loss of MCL-1 expression. In addition, it has
been shown that the pro-apoptotic BH3-only BCL-2 family protein Noxa, specifically interacts
with MCL-1 to inactivate MCL-1 function. Based on these observations, we hypothesized that
modulation of Noxa/MCL-1 axis could mimic paclitaxel-induced cell death. Here, we found that
down-regulation of MCL-1 induced cell death in all breast cancer cell lines that we tested, but not
in a non-transformed breast epithelial cell line. In contrast, Noxa overexpression induced MCL-1

degradation and cell death in some cell lines (Noxa-sensitive), while in others Noxa
overexpression neither changed MCL-1 levels nor induced cell death (Noxa-resistant). Noxa
strongly interacted with MCL-1 in the Noxa-sensitive cell line, but not in the Noxa-resistant cell
line. Based on these findings, the overexpression of Noxa might have two different mechanistic
effects on MCL-1 levels in the breast cancer cell lines (induction of MCL-1 degradation or no
effect on MCL-1). In Noxa-sensitive cells, the finding could be used as a potential therapeutic
strategy for the treatment of breast cancer.

CHAPTER 1: INTRODUCTION
1.1 Cancer
Cancer is a leading cause of death worldwide. Lung, prostate, colorectal and breast cancers are
responsible for the most cancer-related deaths each year (www.wcrf.org). In the United States,
cancer is the second most common cause of death (exceeded only by heart disease) and in 2014,
nearly 600,000 Americans are expected to die from this terrible disease (www.cancer.gov).
Statistical data from the years 2005-2009, showed that in men cancer incidence rates were
reduced by 0.6% and remain stable in women per year. Additionally, cancer death rates declined
in men by 1.8% and by 1.5% in women each year (Siegel et al., 2013).
Cancer refers to a group of more than 100 diseases in which abnormal cells divide uncontrollably
and are capable of invading other tissues. These cancerous cells can spread to different parts of
the body through the blood and lymph systems. Cancer types can be grouped into broader
categories. The main categories of cancer include:
•

Carcinoma - cancer that arises from epithelial tissues that line or cover internal organs or
the outside of the body (skin). There are two major carcinoma subtypes: adenocarcinoma
- which are tumors that develop in the lining or inner surface of an organ or gland, and
squamous cell carcinoma - which are tumors that arise in the squamous epithelium
(epithelial cells that line and protect other cells) (www.cancer.gov).
Carcinomas account for 80 to 90 percent of all cancer cases in the Western World
(Weinberg, 2007)

•

Sarcoma - cancer that originates in supporting and connective tissue including bone,
cartilage, fat, muscle, and blood vessels (www.cancer.gov). Most commonly sarcomas
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•

develop as a painful mass on the bone and occur predominantly in young adults. In
oncology clinics, 1% of the tumors encountered are sarcomas (Weinberg, 2007).

•

Leukemia - cancer that originates in blood-forming tissue such as the bone marrow and
causes abnormal hematocytes to be produced and enter the blood stream. Leukemia is
characterized as the overproduction of immature white blood cells that do not perform
optimally. As a result, the patient is more prone to infections.

•

Lymphoma – cancer that develops in the glands or nodes of the lymphatic system.
Unlike leukemias, lymphomas are solid cancers.

•

Myeloma - cancer that begins in the plasma cells of the bone marrow.

•

Central nervous system cancers - cancers that originate in the tissues of the brain and
spinal cord.

•

Cancer can be caused by both external and internal factors such as tobacco, obesity,
specific infections (Helicobacter pylori, Human papilloma virus, and Hepatitis B and C
virus), reproductive behaviors, the use of exogenous hormones, consumption of red and
processed meat, inherited or acquired genetic mutations, and sunlight. (www.cancer.org).

1.2 Breast Cancer
Breast cancer is the most common cause of cancer-related death among women and the most
frequently diagnosed type of cancer among females worldwide (Jemal et al., 2011). In the United
States alone, 1 out of every 8 women is estimated to be diagnosed with breast cancer annually
(www.breastcancer.org). The World Health Organization states that since 2008, the incidences of
breast cancer have increased by more than 20% while mortality rates have increased by 14%.
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Breast cancer can be classified into molecular subtypes using biological markers that includes
the presence or absence of Estrogen receptors (ER+/ER-), Progesterone receptors (PR+/PR-), and
Human epidermal growth factor receptor 2 (HER2+/HER2-). Therefore, breast cancer can be
divided into 2 broad groups: ER and/or PR-positive and ER and/or PR-negative (Rakha et al.,
2008).
In addition, the ER/PR-positive classification can be sub-divided into two groups referred to as
Luminal A and Luminal B tumors depending on the levels of expression of HER2 (Schnitt,
2010). The Luminal A subtype makes up about 40% of breast cancers and they are defined by
their lack of HER2. Luminal A tumors constitute the most common breast cancer subtype and
they are usually slow growing and less aggressive with the most favorable short term prognosis.
Luminal B tumors represent 10%~20% of breast cancers and are distinguished by their
expression of HER2 or high cell proliferation rates. In general, luminal tumors often present a
positive mean of prognosis due to the presence of various hormone receptors (ER, PR, and
HER2) (Zhang et al., 2014).
Endocrine therapy is the first line of treatment of luminal type breast cancer and involves the
inhibition or blocking of hormones. Normally, Luminal A tumors are associated with the most
favorable short term prognosis versus Luminal B tumors. This association is in part due to the
fact that the expression of hormone receptors is predictive of a favorable response to hormonal
therapy. Nonetheless, about 30% of ER+ breast cancers are resistant to hormonal therapy, which
suggests that other therapeutic approaches, are required for more effective results (Blows et al.,
2010).
ER/PR-negative breast cancers can be sub-divided into two groups characterized by their
expression of HER2. These include tumors which overexpress HER2 or tumors that are HER23

negative. HER2 overexpression is identified in about 15% of invasive breast cancers and is
associated with low ER expression. HER2 is a transmembrane protein which is part of a family
of receptors that include EGFR/HER1, HER2, HER3, and HER4. These receptors are responsible
for regulating a complex signal transduction cascade that influences many cellular processes
including cell cycle progression, cell survival, cell proliferation, and cell motility. HER2
overexpression results in the continual activation of a growth signaling pathway and contributes
to the propagation of breast cancer cells (Slamon et al., 1987) Thus, HER2 positive breast tumors
are likely to be aggressive, fast growing, and less receptive to hormonal treatment. In spite of
these characteristics, pharmacological treatments that target HER2 have resulted in promising
outcomes (Perou et al., 2000). One popular pharmacological treatment involves trastuzumab
(Herceptin), a monoclonal antibody known to bind to the extracellular domain of HER2, which
ultimately blocks the downstream signaling pathways in cancer cells but not in normal cells.
Trastuzumab usage in combination with chemotherapy has proven to be an especially effective
treatment for advanced-stage breast cancer that reduces the risk of relapse (Gajria and
Chandarlapaty, 2011).
Between 12% and 24% of breast cancers are considered triple negative (TN) belonging to the
basal-like subtype. Triple negative cells do not express the ER, PR, and HER2 (ER-/PR-/HER2-)
(Sorlie et al., 2001; Bertucci et al., 2000; Bertucci et al., 2004). Therefore, TN breast cancer cells
do not respond to hormonal therapy (such as tamoxifen or aromatase inhibitors) or therapies that
target specifically HER2, such as trastuzumab.
Chemotherapy is typically the only therapeutic option to treat TN breast cancer due to their lack
of hormonal receptors. Examples of chemotherapeutic agents are anthracycline and
anthracycline/taxane which offer positive initial effects in the treatment of TN tumors, but a
4

rapid relapse rate. Several emerging agents are currently under clinical trials for the treatment of
TN breast cancer. Such agents include platinum chemotherapeutic drugs combined with poly
(ADP-ribose) polymerase 1 (PARP1) inhibitors, which hinder DNA repair in cancer cells The
majority of tumors with BRCA1 (tumor suppressor gene) dysfunctions are TN and have a
deficient double-stranded DNA break repair. Thus, these tumors are more sensitive to PARP1
inhibitors. (Ovcaricek et al., 2011).

1.3 Paclitaxel Treatment
Paclitaxel (Taxol), a taxane plant product (Figure 1), is one of the most effective broad-spectrum
anti-cancer agents that are recognized for the treatment of a variety of cancers including breast,
lung, ovarian, head and neck as well as Kaposi's sarcoma. Paclitaxel was discovered in 1967 at
the Research Triangle Institute (North Carolina, USA) when it was isolated from the bark and
needles of the Pacific Yew evergreen tree (“Taxus brevifolia”) (Jordan et al., 2004). Paclitaxel
was approved by the FDA in 1992 and has since been used with high clinical frequency. Whereas
other drugs like colchicine (a medication for the treatment of gout) cause the depolarization of
microtubules, paclitaxel halts their function by having the opposite effect of hyper-stabilizing
their structure. Particularly, paclitaxel binds to the β subunit of tubulin. Tubulin is the protein that
polymerizes into long filaments that form microtubules- hollow fibers which serve as a “skeletal”
system for a living cell. By binding to tubulin and causing the protein to lose its flexibility,
paclitaxel prevents a cell from dividing (Figure 2). As a result, the microtubule/paclitaxel
complex does not have the ability to disassemble. This complex harmfully affects cell function
because the shortening and the lengthening of microtubules (called dynamic instability) is
necessary for their normal transport of cellular material in the cell (Chu et al 2013). Also, during
5

mitosis, microtubules are responsible for positioning the chromosomes during their replication
following separation into the two daughter-cell nuclei. In addition to stabilizing microtubules,
paclitaxel can sequester free tubulin resulting in the effective depletion. Normal cells are also
affected adversely, but since cancer cells divide much faster than non-cancerous cells, they are far
more susceptible to paclitaxel treatment (Hernandez et al., 2007)
The resistance of cancer cells to chemotherapeutic drugs represents a major problem in cancer
treatment. Although Paclitaxel has proven effective for the treatment of cancer, patients often
experience relapse after initially responding to paclitaxel. The mechanisms of paclitaxel resistance
include point mutations in tubulin, altered expression of β tubulin isotypes and post-translational
modifications (all of them except for acetylation) to tubulin. Molecular modifications to
regulatory proteins involved directly in the function of microtubules (Stathmin, a microtubule
destabilizer and MAP4, a microtubule stabilizer) can also affect paclitaxel sensitivity in a cell
(Orr et al., 2003).

Figure 1: Structural formula of Paclitaxel. The chemical name for Paclitaxel is 5β, 20-Epoxyl,2α,4,7β,10β,13α-hexahydroxytax-l l-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)N-benzoyl-3-phenylisoserine (Orr et al., 2003).
6

Figure 2. Paclitaxel as a mitotic stabilizer. (A) Normal metaphase spindle. Microtubules are
shown in red and chromosomes in light blue. (B) Paclitaxel binds and stabilizes microtubules
blocking cell division (modified from Jordan et al., 2004)

1.4 Apoptosis
Apoptosis (from Ancient Greek apo “away from” and ptosis “falling”) is the process of
programmed cell death that regulates cell proliferation in response to cell damage. Cell death is
essential for proper homeostasis and adaptation to the changing environment. Dysregulation of
apoptosis may result in the manifestation of cancer and autoimmunity (resistance to apoptosis).
Meanwhile, excessive cell death gives rise to cardiovascular diseases and neurodegenerative
disorders such as Alzheimer, Parkinson, and Huntington disease. Thus, apoptosis regulation is
vital for the proper function of the body.
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Apoptosis is characterized by cell shrinkage, active membrane blebbing, chromatin condensation
and fragmentation, cleavage of DNA and loss of adhesion to the surrounding environment (cells,
tissues) (Nishida et al., 2008; Ouyang et al., 2012). Other types of cell death include autophagy
and necrosis. Autophagy differs from apoptosis in that it involves a cellular mechanism of selfeating and often occurs when apoptosis is blocked. Necrosis is characterized by the swelling and
bursting of cellular organelles eventually decomposing, and occurs when the plasma membrane is
ruptured or when there is a drastic decrease of energy in the cell. Apoptosis occurs by two main
pathways: the extrinsic or cytoplasmic pathway, and the intrinsic or mitochondrial pathway
(Figure 3). Both pathways ultimately activate a cascade of Caspase proteases (Ghobrial et al.,
2005). The extrinsic pathway (Figure 3) involves the death receptors on the cell surface. When
these death receptors [such as FAS and TNFR1 (tumor necrosis factor receptor)] bind to their
respective ligands (Fas-L and TNF, respectively), the intracellular regions of the receptors engage
a specific adapter molecule that in turn will bind and activate an initiator caspase. The initiator
caspase will later cleave and activate executioner caspases and apoptosis will follow. In the case
of Fas-Fas-L, this complex recruits FAS-associated death domain protein (FADD) and procaspase-8 that in turn activates caspase-8, which proceeds to activate caspase-3 leading to
apoptosis (Wajant, 2007)
The intrinsic pathway (Figure 3) engages a set of related proteins called the BCL-2 family
proteins which regulate cell death through either induction or inhibition. This pathway of cell
death is engaged by many factors including cell stresses, cytoskeletal disruption, DNA damage
and many others. The intrinsic pathway involves the activation of effector proteins that make the
holes in the outer mitochondrial membrane [Mitochondrial Outer Membrane Permeabilization
(MOMP)] in order to release cytochrome c (Green, 2011). Ultimately, cytochrome c translocates
8

from the mitochondrial intermembrane space to the cytosol and engages APAF1 (apoptotic
protease activating factor 1), which induces apoptosome formation and then activates caspase-3
leading to apoptosis (Youle and Strasser, 2008).

Figure 3. Schematic of the extrinsic and intrinsic pathways of apoptosis (modified from
Youle and Strasser, 2008).
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1.5 BCL-2 Family of Proteins
The BCL-2 family proteins (B cell lymphoma-2) are an assortment of related molecules found not
only in humans but in many other species including Caenorhabditis elegans, Drosophila,
zebrafish, and mice. These species, utilized as study models, are of great importance in the
investigation of BCL-2 family proteins and apoptosis. Although the sequences of most BCL-2
family proteins are quite dissimilar from one another, they all possess short regions known as
BCL-2 homology (BH) domains (Figure 4). The number of BH domains can vary from molecule
to molecule, with some having only one BH domain, and others having up to four (BH1, BH2,
BH3, BH4). The BCL-2 family proteins can be described using three different classifications
based on the structure and function (Figure 4). The first classification refers to the multidomain
pro-apoptotic BCL-2 effectors, which stimulate apoptosis by triggering MOMP. This class
includes BAK and BAX among others. The second classification refers to the anti-apoptotic
BCL-2 proteins, which prevent apoptosis by stopping MOMP. Anti-apoptotic proteins include
BCL-2, BCL-XL, and MCL-1 among others. Lastly, a subfamily of molecules, the BH3-only
proteins, shares only the BH3 domain in their sequence homology. This family functions by
regulating the aforementioned pro-apoptotic or anti-apoptotic BCL-2 molecules by proteinprotein interaction. The BH3-only members include BIM, BID, PUMA, and Noxa (Green, 2011).
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Figure 4: Sequence homology of the BCL-2 family of proteins. All of the BCL-2 family of
proteins contains short BH (BCL-2 homology) domains in common.

Although BAK and BAX belong to the pro-apoptotic BCL-2 effectors, they are quite different.
BAK is tethered to the mitochondria in the cell. In contrast, BAX is soluble in the cytosol but
moves to the mitochondria when apoptosis is induced (Longuet et al., 2004) When both proteins
are activated, they bury themselves in the mitochondrial outer membrane where they oligomerize
and form holes. These holes allow the passage of large molecules (e.g. cytochrome c) through the
membrane.
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Anti-apoptotic BCL-2 proteins prevent the oligomerization of BAK and BAX in order to block
MOMP and stop apoptosis. To exert this function, the BH3 domain of BAK and BAX needs to
bind to the BH groove of the anti-apoptotic BCL-2 proteins. This groove is present in all of the
anti-apoptotic BCL-2 proteins and is critical for their function.
These BH3 regions are not exposed in the native proteins. They can only interact if they are
embedded in a hydrophobic environment as that of the outer mitochondrial membrane.
Furthermore, biochemical evidence shows that activation of BAK exposes its BH3 domain
allowing another BAK molecule (with its exposed BH3 domain) to bind and form an oligomer.
Instead, anti-apoptotic BCL-2 proteins bind to the exposed BH3 domain preventing this BAKBAK interaction which is required for MOMP (Willis et al., 2005).
The BH3-only proteins also bind to the BH grooves of the anti-apoptotic BCL-2 proteins.
Generally, the BH3-only proteins are characterized by their function because their BH3 region is
not conserved in these molecules. They can interfere with the ability of an anti-apoptotic protein
to bind to the BH3 domains of other proteins (ex. effector proteins BAK and BAX) and thus,
neutralizing them. Furthermore, neutralization depends greatly on how well the anti-apoptotic
protein binds to the BH3-only protein (binding specificities) and how much BH3-only protein is
readily available for binding (Chipuk et al., 2010) .
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Figure 5: The BCL-2 family proteins as the main players of the intrinsic pathway. The BH3only proteins promote MOMP and apoptosis through the activation of BAK and BAX. The antiapoptotic BCL-2 proteins prevent by protein-protein interaction.

1.6 MCL-1 and NOXA
An anti-apoptotic BCL-2 family member, MCL-1 was originally identified in 1993 in the
differentiating myeloid leukemia cell line (Kosopas et al., 1993). The human MCL-1 protein
consists of 350 amino acid residues and is critical for the regulation of cell death and survival in
both normal and cancer cells (Michels et al., 2005). Furthermore, MCL-1 deletion in mice results
in an embryonic-lethal phenotype, suggesting a significant role in early development
(Rickenberger et al. 2000). MCL-1 prevents cell death by sequestering pro-apoptotic family
members such as the BH3-only group (Noxa, BID, BIM) and the multidomain pro-apoptotic
effector proteins. (BAK, BAX) (Gelinas et al., 2005). MCL-1 protein has a high turnover rate in
cells and its levels are actively regulated by phosphorylation/ubiquitination followed by
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proteasomal degradation. For example, GSK3 can phosphorylate MCL-1 to target it for
degradation. MULE, an E3 ligase, ubiquitylates MCL-1 for degradation (Mojsa et al., 2014).
Noxa is a pro-apoptotic BH3-only molecule that consists of 54 amino acid residues in humans.
The gene of Noxa was originally cloned as a p53 target gene. The tumor suppressor p53 induces
apoptosis in cells exposed to lethal stresses. It has been shown that blocking endogenous Noxa
suppresses p53-dependent apoptosis. Noxa is known to affect the function of MCL-1 by direct
binding. Then, Noxa triggers the ubiquitin-proteasomal degradation of MCL-1 at the
mitochondria, but the exact mechanism remains unclear. The degradation of MCL-1 in turn helps
initiate the apoptotic cascade. MCl-1 degradation allows for the pro-apoptotic effector protein
BAK to be unleashed (MCL-1 binds to BAK keeping it inactive) from the MCL-1-BAK complex
promoting cell death (Oda et al., 2000).

14

Figure 6: Noxa- induced MCL-1 degradation and BAK activation. In the presence of MCL-1,
BAK is retained in its inactive form in the MCL-1/BAK complex. The apoptotic protein Noxa can
sequester MCL-1, inducing BAK release and activation, oligomerization and eventually cell death
(modified from Willis et al., 2005).
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1.7 Previous studies
When cells undergo paclitaxel-induced cell death, the BCL-2 family-dependent mitochondrial
apoptotic pathway is activated. In the previous study, our lab has shown that inactivation of BAK
by gene knockout in mouse embryonic fibroblasts or by shRNA-mediated knockdown in human
breast cancer cells becomes more resistant to paclitaxel. In contrast, paclitaxel sensitivity is not
affected by inactivation of BAX, suggesting that paclitaxel-induced apoptosis is BAK-dependent,
but BAX-independent. In human breast cancer cells, paclitaxel treatment results in MCL-1
degradation which is prevented by a proteasome inhibitor. BAK is associated with MCL-1 in
untreated cells and becomes activated in concert with loss of MCL-1 expression and its release
from the complex. Thus, paclitaxel-induced apoptosis is mediated by the protein BAK through
MCL-1 degradation (Miller et al., 2013).

16

Figure 7: Schematic of Paclitaxel-dependent MCL-1 degradation. Paclitaxel-induced
apoptosis involves MCL-1 degradation allowing the release and activation of BAK leading to cell
death.
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1.8 Hypothesis
In addition to our previous studies, it has been demonstrated that Noxa specifically interacts with
MCL-1 to inactivate MCL-1 function (Nakajima et al., 2014). Thus, our hypothesis is that
modulation of the Noxa/MCL-1 axis could mimic paclitaxel-induced cell death in breast cancer
cells. It can be surmised that either down regulation of MCL-1 or overexpression of Noxa in
cancer cells could induce cell death.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Cell lines and Cell Culture
MDA-MB-231, MDA-MB-468, Hs578T, BT-20, SKBR-3, MCF7, T47D, BT-474 breast tumor
cell lines and 293T cells were purchased from the American Tissue Culture Collection (Manassas,
VA). ZR-75 breast cancer cells were kindly provided by Dr. David Gewirtz (Virginia
Commonwealth University, Richmond, VA). MDA-MB-231/shMCL-1, MDA-MB-468/shMCL1, Hs578T/shMCL-1, BT-20/shMCL-1, SKBR-3/shMCL-1, MCF7/shMCL-1, T47D/shMCL-1,
BT-474/shMCL-1, ZR-75/shMCL-1 and MCF-10A/shMCL-1 cells were maintained with the use
of puromycin (Sigma, St. Louis, MO) at a 1 µg/mL concentration for selection. MDA-MB231/Noxa WT, MDA-MB-468/Noxa WT, Hs578T/Noxa WT, BT-20/Noxa WT, SKBR-3/Noxa
WT, MCF7/Noxa WT, T47D/Noxa WT, BT-474/Noxa WT, ZR-75/Noxa WT and MCF-10A
Noxa WT cells were maintained using G418 (Sigma) at 0.4 mg/mL concentration for selection.
All cells (except for MCF-10A) were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Invitrogen, Grand Island, NY ) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Gemini Bio-Products, West Sacramento, CA) and 5% 100 mg/ml penicillin
G/streptomycin (Invitrogen) at 37°C in a humidified, 5% CO2 incubator. MCF-10A cells were
cultured using DMEM/F12 (Invitrogen) supplemented with 5% horse serum, mammary epithelial
growth supplement (Invitrogen), 100 ng/ml cholera toxin, and 5% 100 mg/ml penicillin
G/streptomycin at 37°C in a humidified, 5% CO2 incubator.
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2.2 Chemicals and Antibodies
Paclitaxel was purchased from Sigma. Cell proliferation reagent WST-1 was purchased from
Roche Diagnostics (Mannheim, Germany). Antibodies were purchased as follows: BIM (2933S),
BCL-XL (2764S), BID (2002), GAPDH (2118P), Anti-mouse IgG HRP-linked (7076S), and Antirabbit IgG HRP-linked (7074S) from Cell Signaling Technology (Beverly, MA); MCL-1(ADIAAP-240-F) from Enzo Life Sciences (Farmingdale, NY); BCL-2 (2870S) from Sigma; AlphaTubulin (sc-8035), and BAX (sc-493) from Santa Cruz Biotechnology (Santa Cruz, CA); BAK
(06-536) from EMD Millipore (Darmstadt, Germany); and Noxa (MA1-41000) from Thermo
Fisher Scientific (Waltham, MA).

2.3 Plasmid Transfection and Lentivirus Infection
The lentiviral short-hairpin RNA (shRNA)-expressing construct were purchased from Sigma.
Flag-tagged Noxa cDNA was cloned into pCDH-EF1-MCS-IRES-neo (System Biosciences,
Mountain View, CA, USA). The constructs were transfected into 293T packaging cells along with
the packaging plasmids (psPAX2 and pMD2.G) and the lentivirus-containing supernatants were
used to transduce human breast cancer cells.
To generate recombinant lentivirus, the 293T cells (1 x 106 cells total) were plated on a 10cm cell
culture dish. Transfection steps were carried out 2 days later as the 293T cells became
approximately 70% confluence. First, 5 μg of DNA (including 2.5 μg of interested lentiviral
expression constructs and 2.5 μg of lentiviral packaging plasmids) were mixed into 200 μL of
(Optimum, Life Technologies, Grand Island, New York) medium (Invitrogen). In a separate tube,
15 μL of Endofectin (Gene Copoeia, Rockville, MD) was diluted into another 200 μL of medium.
20

Next, the diluted Endofectin reagent was added drop wise into the DNA solution while gently
vortexing the DNA-containing tube. The mixture was incubated for 15-20 minutes at room
temperature. Finally, the DNA-Endofectine mixture was added gently into the 293T cells. The
medium was replaced after 14-18 hours. After two days of incubation, the lentivirus shed into the
medium was collected and used to infect the breast cancer cells of interest.

2.4 Cell Toxicity Assay
Breast cancer cells were seeded in triplicate in microtiter plates (96 wells) with a concentration of
1x104 cells per well in 150 µL medium. Next day, cells were treated with different concentrations
of paclitaxel and after 72 hours 4 µL of WST-1 reagent were added to the cells. Cytotoxicity of
paclitaxel was determined by the WST-1 assay, which is based on the tetrazolium salt WST-1 (4[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulphonate), according to the
manufacturer’s instruction (Roche). The absorbance of the samples was measured using a
microplate ELISA reader. The wavelength for measuring the absorbance for the reagent was 450
nm.

2.5 Western Blot Analysis and Immunoprecipitation
For Western blot analyses, whole cell lysates were prepared with CHAPS lysis buffer. CHAPS is
a mild detergent which maintains the native structure of the protein in order to observe proteinprotein interaction. CHAPS lysis buffer ([20 mM Tris (pH 7.4), 137 mM NaCl, 1 mM
dithiothreitol

(DTT),

1%

CHAPS

(3-[(3
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Cholamidopropyl)

dimethylammonio]-1-

propanesulfonate), contains a 1:200 ratio of protease inhibitor (Sigma Aldrich), and a 1:100 ratio
each of phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich). Protein concentrations were
determined by spectrophotometric analysis using the Bradford method (Bio-rad, Hercules, CA).
Equal amounts of each protein sample were loaded into an SDS-polyacrylamide gel,
electrophoresed at 200 V for 1 hour, and transferred onto a Nitrocellulose membrane (Fischer
Scientific, Pittsburgh PA). The membrane was blocked for 30 minutes in a blotting solution [5%
skim milk in PBST (1 x PBS with 0.1% Tween-20)]. After the blocking step, the membrane was
incubated with the respective antibodies overnight at 4 °C. The following day, after three separate
5 minutes washes with PBST, the membrane was incubated with the appropriate secondary
antibody for 1 hour at room temperature, immediately followed by another three washes at 5
minutes apiece in PBST. The membrane was then developed using Pierce ECL 2 Western
Blotting Substrate (Thermo Fisher Scientific). Primary antibodies for BIM, BCL-XL, Cleaved
PARP, GAPDH, BCL-2, BAX, BAK, and Alpha-Tubulin were used at a 1:1000 dilution. MCL-1
antibody was used at a 1:5000 dilution, while Noxa antibody was used at a 1:250 dilution.
Secondary antibodies for HRP-linked anti-mouse- and anti-rabbit-IgG were used at a 1:2000
dilution.
For immunoprecipitation (IP), cell lysates were prepared with CHAPS lysis buffer. 500 µg of
protein was incubated with MCL-1 or Noxa antibodies at 4°C for 2-3 hours. After the incubation
period, the antibody-protein complex was captured with Protein A/G UltraLink Resin (Thermo
Fisher Scientific) and the beads were washed with the CHAPS buffer three times. The beads were
then suspended in 50 µL of the CHAPS buffer with 5x sample buffer. Samples were separated
using SDS-PAGE.
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2.6 IC50 Calculations
IC50 (half maximal inhibitory concentration) for paclitaxel cytotoxicity was calculated for each
cell line in this study. IC50 is a measure of the effectiveness of a substance in inhibiting a specific
biological or biochemical function. This quantitative measure indicates how much of a particular
drug or other substance (inhibitor) is needed to inhibit a given biological process (or component
of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. For this study we used
the Image J software to calculate the IC50 for each cell line using the measurements obtained from
the microplate (ELISA) reader.
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CHAPTER 3: RESULTS

Section 3.1: Breast cancer cell lines and their molecular characteristics
Each of the following breast cancer cell lines was used in this study and their main characteristics
have been outlined in Table 1.

Table 1. Molecular Classification of Breast Carcinoma
Subtype

Receptor
Status

Responsiveness to Therapy

Cell Lines

Luminal A

ER+
PR+/HER2-

endocrine and chemotherapy
responsive

MCF-7, T47D

Luminal B

ER+
PR+/HER2+

usually endocrine responsive,
variable to chemotherapy

BT474, ZR75

endocrine nonresponsive, often
chemotherapy responsive

MDA-MB-468,
MDA-MB-231,
Hs578T, BT20

trastusumab responsive,
chemotherapy responsive

SKBR3

Basal (TN)

Her2

ERPRHER2ERPRHER2+

In addition to the various breast cancer cells in our study, we also used immortalized normal
breast epithelial cells (non-cancerous) – MCF-10A.
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Section 3.2: Knockdown of MCL-1 induces cell death in breast cancer cells.
In order to examine whether down-regulation of MCL-1 in breast cancer cell lines could induce
cell death, we introduced short-hairpin RNA (shRNA) for MCL-1to knock-down the MCL-1
expression and scrambled-shRNA as a control. Figure 8 shows representative cell lines in which
MCL-1 was down-regulated by shMCL-1. All breast cancer cell lines examined in this study
resulted in cell death upon MCL-1 knock-down (Table 2). In contrast, MCF-10A did not show
cell death in the same condition. These results suggest that MCL-1 expression in breast cancer
cells is critical to maintain cell survival.

Hs578t

SKBR3

Control shMCL-1

Control shMCL-1

MCL-1

MCL-1

Tubulin

Tubulin

Figure 8. MCL-1 knock-down in cell lines Hs578t and SKBR3. Cells were infected with MCL1 knock-down or non-targeting shRNA-containing lentivirus. MCL-1 expression levels were
determined using Western blot analysis.
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Section 3.3: Overexpression of Noxa in breast cancer cells induces survival or cell death.
It has been proposed that Noxa sequesters MCL-1 allowing the effector protein BAK to be
released, resulting in cell death induction. Therefore, we want to examine if up-regulation of
Noxa in breast cancer cells can induce apoptosis. We introduced Noxa cDNA using lentivirusmediated transfection. As a control, a lentiviral-vector alone was introduced. Noxa overexpression
induced cell death in the following breast cancer cell lines: MDA-MB-468, BT-20, SKBR-3 and
MCF-7 (Noxa-sensitive). In contrast, Noxa overexpression did not result in substantial amounts
of cell death in the following breast cancer cell lines: MDA-MB-231, Hs578T, ZR75, T47D, BT474, nor in the non-cancerous breast cell line MCF-10A (Noxa-resistant) (Table 2). Based on
these results we speculate that the availability of Noxa is not the only factor when inducing cell
death by MCL-1 degradation in some breast cancer cell lines. Furthermore, these results suggest
that there are obvious molecular differences among the various breast cancer cell lines studied.
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Table 2. Results of MCL-1 knock-down and Noxa overexpression in breast cancer cells and
MCF-10A.
Molecular Subtype

Knock down of
MCL-1

Enforced expression of Noxa

MDA-MB-231

Basal-like subtype

death

survive

MDA-MB-468

Basal-like subtype

death

death

Hs578 T

Basal-like subtype

death

survive

BT-20

Basal-like subtype

death

death

SKBR-3

HER2 subtype

death

death

MCF-7

Luminal A subtype

death

death

ZR-75-1

Luminal A subtype

death

survive

T47D

Luminal A subtype

death

survive

BT-474

Luminal B subtype

death

survive

Basal-like subtype

survive

survive

Breast Cancer Cell Lines

Immortalised normal
breast cells (noncancerous)
MCF-10A

Table 2. Results of MCL-1 knock-down and Noxa overexpression in breast cancer cells and
MCF-10A. None of the breast cancer cell lines tested survived the MCL-1 knock-down
condition. In contrast, Noxa overexpression resulted in cell survival in MDA-MB-231, Hs578t,
ZR-75-1, T47D, and BT474. Noxa overexpression also resulted in cell death in cell lines MDAMB-468, BT-20, SKBR3, and MCF-7. Noxa overexpression in the triple negative breast cancer
cell lines resulted in the survival of MDA-MB-231 and Hs578t; and cell death of cell lines MDAMB-468 and BT-20 (highlighted in red above). MCF-10A (normal breast cells) survived both
conditions.
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Section 3.4: The expression of the BCL-2 family proteins in TN breast cancer cells.
In order to further study the differences of Noxa-induced cell death among breast cancer cell lines
in particular triple negative cells, we analyzed the endogenous expression levels of various BCL-2
family proteins. Protein expression levels were determined by Western blotting. GAPDH (a
housekeeping protein in cells) was utilized as a control to demonstrate equal loading.
MCL-1 expression levels were relatively higher in MDA-MB-468 and Hs578T which appeared in
comparison to MCF-10A, MDA-MB-231, and BT-20. Noxa expression levels were significantly
higher in cell lines MDA-MB-231 and Hs578t. BAK expression levels were relatively the same
for all cell lines except for BT20. BIM expression levels were significantly higher in MCF-10A,
MDA-MB-468, and BT20 (Figure 9). The rest of the BCL-2 family proteins analyzed were
similar in expression levels among the various cell lines.
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A.

Variable Noxa
expression levels

MCL-1
Noxa
BAK
BAX
Tubulin
S: survive
D: death

Noxa Overexpression
B.

BCL-xL
BCL-2
BID
BIM

Figure 9: Expression levels of the BCL-2 family of proteins in TN breast cancer cells.
Different BCL-2 family proteins expression levels in TN breast cancer cells suggesting molecular
differences among them.
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Section 3.5: The interaction of MCL-1 and Noxa is weak in Hs578 and strong in BT-20.

Overexpression of Noxa in the TN cells caused cell death in BT-20 cells but not in Hs578T cells.
Furthermore, Western blot results (Figure 9) showed that the level of MCL-1 was decreased when
Noxa was overexpressed in BT-20 cells, but not in Hs578T cells. Therefore, we wanted to further
analyze the interaction of Noxa and MCL-1 in these two cell lines. We performed coimmunoprecipitation experiments to observe such interaction. Transfected Flag-tagged Noxa was
equally immunoprecipitated with anti-Flag antibodies. However, the amount of coimmunoprecipitated MCL-1 was much less in Hs578T than in BT-20 (Figure 10). These results
suggested that the interaction between Noxa and MCL-1 was much weaker in Hs578T resulting in
cell survival. In contrast, Noxa and MCL-1 interaction was stronger upon Noxa overexpression
in BT-20 cells, which caused MCL-1 degradation- cell death.
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Noxa

Control

Noxa

Control

Survive Death
Hs578T BT20

Noxa
MCL-1 degradation
in BT20 cells

MCL-1

Cleaved MCL-1?

Tubulin

Figure 10. Noxa overexpression and its effect on MCL-1 protein levels in Hs578T and BT20. Noxa up regulation induces MCL-1 degradation in BT-20 but not in Hs578T. We speculate
that the band below MCL-1 might be the cleaved form of MCL-1 after caspases are activated.
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Survive Death

A.

Hs578T BT-20
Flag-Noxa

- +

-

+

Hs578T BT-20

- +

-

+

MCL-1
Noxa
Tubulin

IP: α-Flag

Input

B.

Death Survive
MB-468 MB-231
Flag-Noxa

- +

-

+

MB-468 MB-231

- +

-

+

MCL-1

MCL-1
Noxa

IP: α-Flag

Input

Figure 11. IP results of Noxa overexpression and MCL-1 in TN cells. Overexpression of Noxa
resulted in Hs578T and MDA-MB-231 survival. In contrast in cell lines BT-20 and MDA-MB468 Noxa overexpression resulted in cell death. Noxa-MCL-1 interaction shown here suggests
weak binding in Hs578T and MDA-MB-231 but strong binding in BT-20 and MDA-MB-468 cell
lines
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BT-20 and MDA-MB-468:

Hs578t and MDA-MB-231:

MCL-1
MCL-1
degradation

Noxa

Weak
Binding

Strong
Binding

CELL
SURVIVAL

CELL DEATH

Figure 12. Schematic representation of Noxa and MCL-1 interaction in TN cells. In Hs578t
and MDA-MB-231 cells weak binding of Noxa and MCL-1 (MCL-1 degradation does not occur)
results in cell survival. In BT-20 and MDA-MB-468 cells, strong binding of Noxa and MCL-1
induces MCL-1 degradation resulting in cell death.
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Section 3.6: Paclitaxel sensitivity results of various breast cancer cell lines
In order to examine the correlation between cell death induced by Noxa overexpression and
paclitaxel sensitivity, we treated breast cancer cells with different concentrations of paclitaxel (0,
0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1 µM). Then we determined the IC50 for each cell line
using WST-1 assay (Table 3). Non-cancerous MCF-10A was very resistant to paclitaxel. In
contrast, breast cancer cell lines showed various sensitivities to paclitaxel. For example, ZR-75-1
was very sensitive, MDA-MB-468, T47D and BT-474 are sensitive, while Hs578Twere resistant.
However, all of these cell lines did not show cell death induced by Noxa overexpression (Table 2
and 3). These results suggest that paclitaxel sensitivity may be regulated by more complex
mechanisms.
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Table 3. IC50 values to Paclitaxel in breast cancer
cells and MCF-10A.
Breast Cancer
Cell Lines
MDA-MB-231
MDA-MB-468
Hs578 T
BT-20
SKBR-3
MCF-7
ZR-75-1
T47D
BT-474

Paclitaxel sensitivity IC50 (nM)
57
65
401
174
11
263
0.58
98
74

Immortalised
normal breast
cells (noncancerous)
MCF-10A

933

Table 3. IC50 values to Paclitaxel in breast cancer cells and MCF-10A. IC50 values for various
breast cancer cell lines were calculated by WST-1 assay. MCF-10A IC50 value to Paclitaxel was
also calculated.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS

Paclitaxel, a taxane family member, is widely used in the treatment of several cancers such as
breast, lung, and ovarian. This chemotherapeutic agent causes mitotic arrest although its exact
mechanism remains to be elucidated. Several reports have demonstrated that paclitaxel-induced
cell death involves MCL-1 degradation and the presence of the effector protein BAK. Therefore,
this study aims to mimic paclitaxel-induced cell death by the down regulation of MCL-1 and up
regulation of Noxa in breast cancer cell lines. Results showed that MCL-1 knock-down was fatal
for nine breast cancer cell lines examined (Table 2). Thus, MCL-1 is a critical pro-survival
protein for breast cancer cells. Presumably, MCL-1 protein levels may be strictly controlled in
normal cells. On the other hand, cancer cells may have a vast stock (of MCL-1) to ensure high
levels of MCL-1 in order to escape apoptosis. Moreover, down regulation of the MCL-1 protein
by shRNA knock-down may sensitize paclitaxel-resistant breast cancer cells allowing for better
therapeutic methods.
Noxa overexpression has been shown to sensitize cancer cells to a particular drug treatment such
as a BCL-2 inhibitor, ABT-737, in small cell lung cancer cells (by the induction of MCL-1
degradation leading to apoptosis). For that reason, we examined cell death in breast cancer cells
upon Noxa overexpression. The results showed that the up-regulation of Noxa was lethal in
MDA-MB-468, BT-20, SKBR-3, and MCF-7 but led to the survival of MDA-231, Hs578T, ZR75-1, T47D, and BT-474 (Table 2). These results suggest that in breast cancer cells survived by
Noxa overexpression, another factor (besides solely Noxa availability) is responsible for the
induction of MCL-1 degradation. Perhaps the binding affinity between Noxa and MCL-1 plays a
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significant role in the induction of Noxa-dependent apoptosis. However, the reason for this
difference in binding affinity remains to be elucidated.
Additionally, Noxa overexpression in the TN breast cancer cell Hs578T did not result in MCL-1
degradation. In contrast, we observed MCL-1 degradation in BT-20 cells when Noxa is upregulated (Figure 9) between these cells to the effect of Noxa up-regulation prompted us to
examine the protein-protein interaction of Noxa and MCL-1. We performed immunoprecipitation
to examine such interaction in Hs578T and BT-20. Results obtained from Hs578T (Noxa resistant
cell that did not show MCL-1 degradation) suggested a weak interaction between Noxa and
MCL-1. Contrary, in BT-20 breast cancer cells (Noxa-sensitive cell that showed MCL-1
degradation) a strong protein-protein interaction was observed (Figure 10). These results suggest
that the binding affinity between Noxa and MCL- 1 (either weak or strong) may be of importance
to whether the cell is destined to survive or to perish.
We studied the endogenous expression levels of several of the BCL-2 family proteins in the TN
breast cancer cell lines MDA-MB-231, Hs578T, MDA-MB -468, and BT-20. Although these
cancer cells are similar in that they do not possess the ER, PR, and HER2, they differ in the
expression levels of the BCL-2 family proteins (Figure 8). These differences in the endogenous
levels of the BCL-2 family proteins among the TN breast cancer cells may be important for the
development of more effective cancer treatments. Furthermore, we observed higher expression
levels of the protein Bim in Noxa sensitive cells BT-20 and MDA-MB-468. In contrast, Noxa
resistant cells MDA-MB-231 and Hs578T show low levels of Bim expression. We speculate that
Bim (Bim can interact with all of the anti-apoptotic BCL-2 family proteins) may contribute
alongside Noxa to induce MCL-1 degradation leading to apoptosis.
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These new findings have important implications for overcoming paclitaxel sensitivity and for the
development of innovative and more effective therapeutic drugs. For future studies it will be
significant to study MCL-1 cDNA for mutations, post-translational modifications, or any other
factor that may be contributing to the lack of correlation in Noxa overexpression and MCL-1
degradation in some of the breast cancer cell lines we examined in this study.
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